Minimal Residual Disease Assessment in Lymphoid Malignancies : Episode 10

MRD Negativity in Multiple Myeloma

Aug 28, 2017

MRD Testing

EP: 1.Goals of Therapy in CLL

EP: 2.CLL: Value of MRD Testing

EP: 3.MRD Timepoints in CLL

EP: 4.CLL: MRD Testing Platforms

EP: 5.Understanding MRD Testing in CLL

EP: 6.An Overview of Minimal Residual Disease Testing

EP: 7.How to Properly Utilize MRD Testing

EP: 8.Varying Pertinence: MRD Testing Across Lymphomas

EP: 9.Reliability of MRD Testing: Sensitivity/Specificity

EP: 10.MRD Negativity in Multiple Myeloma

EP: 11.The Value of MRD Testing in Lymphoid Malignancies

Related Videos

In this first episode of OncChats: Examining LIFU–Aided Liquid Biopsy in Glioblastoma, Manmeet Singh Ahluwalia, MD, and Michael W. McDermott, MD, explain how low-intensity focused ultrasound works and the rationale for examining its use in cancer and other conditions.

Claire Roddie, MD

Yael Cohen, MD

Guillermo Garcia-Manero, MD

Amer Zeidan, MBBS

Adam D. Cohen, MD, director, Myeloma Immunotherapy, associate professor in medicine, hematology/oncology, Abramson Cancer Center, University of Pennsylvania

Jeffery Zonder, MD

Natalie S. Callander, MD

Jeffery Zonder, MD

Related Content

Epcoritamab Plus Rituximab/Lenalidomide Produces Responses in High-risk R/R Follicular Lymphoma

Andreeff Sheds Light on the Evaluation of the E-selectin Antagonist Uproleselan in AML

Erdafitinib Confers OS Benefit in FGFR-Altered Urothelial Cancer

FDA Approval Insights: Omidubicel in Blood Cancers Requiring Transplant

Nivolumab With AVD Confers PFS Benefit Vs Brentuximab Vedotin Plus AVD in Advanced-stage Hodgkin Lymphoma

Elranatamab Elicits Responses in Relapsed/Refractory Myeloma After Prior BCMA-directed Therapy

Epcoritamab Plus Rituximab/Lenalidomide Produces Responses in High-risk R/R Follicular Lymphoma

Andreeff Sheds Light on the Evaluation of the E-selectin Antagonist Uproleselan in AML

Erdafitinib Confers OS Benefit in FGFR-Altered Urothelial Cancer

FDA Approval Insights: Omidubicel in Blood Cancers Requiring Transplant

Nivolumab With AVD Confers PFS Benefit Vs Brentuximab Vedotin Plus AVD in Advanced-stage Hodgkin Lymphoma

Elranatamab Elicits Responses in Relapsed/Refractory Myeloma After Prior BCMA-directed Therapy

Epcoritamab Plus Rituximab/Lenalidomide Produces Responses in High-risk R/R Follicular Lymphoma

Andreeff Sheds Light on the Evaluation of the E-selectin Antagonist Uproleselan in AML

Erdafitinib Confers OS Benefit in FGFR-Altered Urothelial Cancer

FDA Approval Insights: Omidubicel in Blood Cancers Requiring Transplant

Nivolumab With AVD Confers PFS Benefit Vs Brentuximab Vedotin Plus AVD in Advanced-stage Hodgkin Lymphoma

Elranatamab Elicits Responses in Relapsed/Refractory Myeloma After Prior BCMA-directed Therapy

Related Content

Reid W. Merryman, MD

Epcoritamab Plus Rituximab/Lenalidomide Produces Responses in High-risk R/R Follicular Lymphoma

Michael Andreeff, MD, PhD

Andreeff Sheds Light on the Evaluation of the E-selectin Antagonist Uproleselan in AML

Erdafitinib reduced the risk of death by 36% vs investigator’s choice of chemotherapy in patients with FGFR2/3-altered metastatic urothelial cancer who were previously treated with anti–PD-1 therapy, according to findings from the phase 3 THOR trial.

Erdafitinib Confers OS Benefit in FGFR-Altered Urothelial Cancer

Mitchell E. Horwitz, MD

FDA Approval Insights: Omidubicel in Blood Cancers Requiring Transplant

Alex F. Herrera, MD

Nivolumab With AVD Confers PFS Benefit Vs Brentuximab Vedotin Plus AVD in Advanced-stage Hodgkin Lymphoma

$Treatment with elranatamab monotherapy produced early, deep, and durable responses in patients with relapsed/refractory multiple myeloma who received a prior BCMA-directed therapy, according to a pooled analysis of the MagnetisMM-1, MagnetisMM-2, MagnetisMM-3, and MagnetisMM-9 trials.$

Elranatamab Elicits Responses in Relapsed/Refractory Myeloma After Prior BCMA-directed Therapy

Latest Conference Coverage

Epcoritamab Plus Rituximab/Lenalidomide Produces Responses in High-risk R/R Follicular Lymphoma

TTFields Plus SOC Improves OS in Metastatic NSCLC After Progression on Platinum-based Chemotherapy

Liso-Cel Leads to Rapid Responses, High Undetectable MRD Rates in Relapsed/Refractory CLL/SLL

Datopotamab Deruxtecan Plus Pembrolizumab With or Without Chemo Produces Responses in Advanced NSCLC

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.